Latest news with #GlenmarkPharma
Mint
3 days ago
- Business
- Mint
Top three stocks to buy today—recommended by Ankush Bajaj for 21 July
Indian stock market benchmarks—the Sensex and the Nifty 50—ended lower on Friday, 18 July, extending losses for the third straight week. The Nifty 50 slipped below the key 25,000 mark, signalling continued pressure on the broader market. Over the past three weeks, the Sensex has shed nearly 2,300 points, or close to 3%, while the Nifty 50 has also declined by around 3%. On Friday, the Nifty 50 fell 143 points, or 0.57%, to close at 24,968.40, while the Sensex dropped 502 points, or 0.61%, to settle at 81,757.73. The broader market also came under pressure, with recent outperformers in the mid- and small-cap segments witnessing a sell-off. The BSE Midcap and Smallcap indices declined 0.62% and 0.64%, respectively. Top 3 stocks recommended by Ankush Bajaj for 21 July: Why it's recommended: Despite the broader market sell-off, SAIL managed to close over 2% higher on Friday, showing strong relative strength. The stock has taken support at the 20-day moving average on the daily chart, and the daily RSI stands at 60, indicating bullish momentum. This resilience suggests that the uptrend may continue in the near term. Key metrics: Support taken at 20-DMA; strength seen despite weak market. Pattern: Bounce from moving average with strong candle formation. RSI: Daily RSI at 60 confirms upward momentum. Technical analysis: The chart indicates strong support and the potential for a move toward ₹145 in the short term. Risk factors: A breakdown below ₹132 would invalidate the setup and invite renewed selling. Buy at: ₹136.45 Target price: ₹145.00 Stop loss: ₹132.00 Why it's recommended: On the daily chart, HDFC AMC has formed a triangle breakout pattern, supported by a strong RSI reading of 74, indicating robust momentum. On lower timeframes, the stock is trading above all key moving averages, which further strengthens the bullish outlook. A continuation of this rally could lead to much higher levels. Key metrics: Triangle pattern breakout on daily chart with high RSI. Pattern: Bullish triangle breakout with volume support. RSI: Strong daily RSI at 74 signals momentum continuation. Technical analysis: The structure suggests an ongoing breakout with scope for further upside towards ₹5,680 and higher. Risk factors: A fall below ₹5,545 would negate the breakout and weaken the trend. Buy at: ₹5,590.00 Target price: ₹5,680.00 Stop loss: ₹5,545.00 Why it's recommended: Glenmark Pharma has formed abullish pennant pattern on the daily chart, indicating a continuation of its recent strong uptrend. The hourly RSI is trending higher at 59, showing that momentum is picking up again after recent profit booking. The stock made new highs recently, and this consolidation phase could lead to a fresh breakout toward lifetime highs. Key metrics: Bullish pennant breakout on the daily chart. Pattern: Pennant pattern with momentum re-emergence. RSI: Hourly RSI at 59 showing strength returning. Technical analysis: The price action suggests that the stock may be ready for another leg up towards ₹2,280, with potential to go even higher. Risk factors: A move below ₹2,194 would invalidate the bullish setup. Buy at: ₹2,225.50 Target price: ₹2,280.00 Stop loss: ₹2,194.00 Market Wrap – 18 July Indian equity markets ended in the red on Friday, 18 July, as sustained selling across key sectors continued to weigh on investor sentiment. Despite brief recovery attempts—particularly in select defensives—broader market momentum remained weak, leading to a negative close across major indices. The Nifty 50 declined 143.05 points, or 0.57%, to settle at 24,968.40, while the BSE Sensex shed 501.51 points, or 0.61%, closing at 81,757.73. The Bank Nifty also ended lower, down 545.80 points, or 0.96%, at 56,283.00, as late-session buying failed to offset earlier losses in financial stocks. From a sectoral perspective, the tone remained largely cautious. The Banking index slipped 0.79%, Financial Services dropped 0.67%, and the Services index declined 0.59%—all reflecting profit booking and a broader risk-off mood in high-beta segments. The Metal sector stood out with a modest gain of 0.37%, offering some support to an otherwise weak market. In stock-specific action, Wipro led the gainers with a 2.25% rise, followed by Bajaj Finance and Tata Steel, which gained 1.63% and 1.17%, respectively—supported by sustained institutional inflows and strength in metals. However, the broader undertone remained bearish. Axis Bank fell sharply by 2.75%, Shriram Finance declined 1.67%, and Bharat Electronics Ltd. dropped 1.44%, reflecting investor caution in previously strong counters. Nifty Technical Analysis Daily & Hourly The Nifty ended Thursday's session on a weak note, closing at 24,968.40, down 143.05 points or 0.57 percent, marking a clear breakdown below the psychological 25,000 mark. This close below a key level indicates a further deterioration in short-term sentiment and suggests that the selling pressure may continue in the coming sessions. Technically, the index is now trading below both the 20-day simple moving average, which stands at 25,318, and the 40-day exponential moving average at 25,038. This structure signals that the upside remains capped unless the index manages to reclaim these moving averages decisively. The hourly chart also shows continued weakness, with Nifty trading below its 20-hour simple moving average of 25,137 and the 40-hour EMA at 25,101. More importantly, the index has broken down from the lower end of a rising wedge pattern, which is a bearish technical formation. This breakdown projects a near-term downside towards the 24,700 level, and if that fails to hold, the next major support lies around 24,500. Momentum indicators are reinforcing this bearish bias. The daily Relative Strength Index (RSI) has slipped to 43, showing a weakening trend, while the hourly RSI has fallen to 30, indicating oversold conditions and persistent intraday selling pressure. The daily MACD remains in positive territory at 38, suggesting that the medium-term trend hasn't entirely flipped bearish, but the hourly MACD has plunged to –65, confirming strong short-term downside momentum. Options data also presents a clearly bearish setup. Total Call open interest stands at 13.61 crore compared to 8.15 crore on the Put side, leading to a net difference of –5.47 crore, indicating aggressive call writing. The highest Call open interest is at the 25,200 strike, with maximum additions at 25,100, reinforcing a strong resistance zone overhead. On the Put side, while the highest OI is at the 24,900 strike, the maximum additions were at 23,050, suggesting that traders are anticipating even lower levels. Intraday changes also support this bearish stance, with Call OI rising by 6.36 crore and Put OI increasing by just 3.08 crore, resulting in a net change of –3.28 crore. Additionally, India VIX rose by 1.33% to 11.39, indicating a slight rise in market volatility and nervousness among participants. In summary, as anticipated in earlier reports, Nifty has now closed below the 25,000 mark, which has triggered a fresh wave of weakness. The index is expected to test the next support around 24,700 on the hourly chart, where a brief pause or consolidation might occur. However, a failure to hold that level could open the doors for further decline towards 24,500. Unless the index reclaims at least 25,318 and then 25,700 levels convincingly, the broader market trend remains fragile and tilted to the downside. Traders are advised to stay cautious and avoid aggressive long positions until signs of a reversal emerge Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
15-07-2025
- Business
- Business Standard
Stock Alert: Tata Tech, HCL Tech, Railtel Corp, Tejas Networks, AstraZenca Pharma
Securities in F&O Ban: Glenmark Pharma, Hindustan Copper and RBL Bank are banned from F&O trading on 15 July 2025. Upcoming Results: GM Breweries, HDB Financial Services, HDFC Life Insurance, Himadri Special Chemicals, ICICI Lombard General Insurance, ICICI Prudential Insurance, Just Dial will declare their results alter today. Stocks to Watch: HCL Technologies consolidated net profit declined 10.77% to Rs 3,843 crore on 0.34% increase in revenue from operations to Rs 30,349 crore in Q1 FY26 over Q4 FY25. Railtel Corporation of India has received the work order worth Rs 2.64 crore from East Central Railway for provision of Kavach (indigenous train collision avoidance system) on low density railway track in 607 km of East Central Railway. Tejas Networks reported consolidated net loss of Rs 193.87 crore in Q1 FY26 compared with net profit of Rs 77.48 crore in Q1 FY25. Revenue from operations fell 87.08% YoY to Rs 201.98 crore in Q1 June 2025. AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 m. Tata Technologies reported 9.84% decline in consolidated net profit to Rs 170.28 crore on 3.22% drop in net sales to Rs 1244.29 crore in Q1 FY26 over Q4 FY25. Brigade Enterprises board has considered and approved the issuance on non-convertible debentures (NCDs) on a private placement basis in one or more tranches for an aggregate amount of up to Rs 1,500 crore.
Business Standard
14-07-2025
- Business
- Business Standard
Stock Alert: Dmart, Ajmera Realty, Rites, RVNL, Indegene, Gland Pharma
Securities in F&O Ban: Glenmark Pharma, Hindustan Copper and RBL Bank shares are banned from F&O trading on 14 July 2025. Upcoming Results: HCLTech, Ola Electric, Rallis India, Tata Technologies, Tejas Networks, Kesoram Industries will announce their quarterly results later today. Stocks To watch: Avenue Supermarts (Dmart)s consolidated net profit fell 0.11% to Rs 772.97 crore despite a 16.28% jump in revenue from operations to Rs 16,359.70 crore in Q1 FY26 over Q1 FY25. Ajmera Realty & Infra reported 65% decline in sales value to Rs 108 crore in Q1 FY26 compared with Rs 306 crore in Q1 FY25. Collection jumped 42% YoY to Rs 234 crore in Q1 FY26, underscoring strong cash flow realization from existing projects. Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. RITES said that it has received an order for undertaking the construction and renovation of Government First Grade College at various locations in Karnataka under the PM USHA Scheme. The project cost, including RITES fees, is Rs 46.82 crore. The project has to be executed within a period of 36 months. Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. Rail Vikas Nigam (RVNL) has been awarded a letter of acceptance (LoA) by the South Central Railway for a significant project valued at Rs 213.22 crore. The contract encompasses the design, supply, erection, testing, and commissioning of an overhead equipment (OHE) upgradation project. NCC announced that it has received a Letter of Acceptance (LoA) worth Rs 2,269 crore from the Mumbai Metropolitan Region Development Authority (MMRDA) for work on the Mumbai Metro Line 6 project. RailTel Corporation of India has received a work order from Indian Overseas Bank, valued at Rs 10.27 crore. The project is scheduled to be executed by 7 August 2025. IRB Infrastructure Developers, along with its InvIT associate IRB Infrastructure Trust, reported combined toll revenue of Rs 1,680 crore for the AprilJune quarter of FY26, marking an 8% year-on-year increase from Rs 1,556 crore in Q1 FY25.
Mint
14-07-2025
- Business
- Mint
Industrial evolution: Indian pharma needs a major R&D-oriented reset
The news that Glenmark Pharma has, via a wholly owned subsidiary, signed an exclusive licensing agreement worth hundreds of millions of dollars with US-based AbbVie for a new experimental cancer treatment is most welcome. It is time Indian pharma moved up the value chain from producing cheap generics—drugs whose patents have expired and can be made by companies other than their originators and licensees—and started creating new lines of therapy. Also Read: Glenmark unit clinches $700mn licensing deal for its cancer drug The industry should come up with entirely new molecules, identify new purposes for old ones, personalize medication at the genomic level, set modern tech-derived protocols and innovate with gene editing. Creating new intellectual property calls for investment, a hardy appetite for risk and the ability to assemble, inspire and deploy talent within an ecosystem that rewards valuable work. Most of all, what it calls for is ambition and the courage to reach above the low-hanging fruit on which our industry has long thrived. Apart from low costs, India has research talent, a population of vast genomic variety and an intellectual-property regime that is sound in principle, although a bit tardy. This mix calls for entrepreneurial vision, sparks of which had lit up the likes of Piramal and Dr Reddy's but have been too few and far between. Also Read: India's pharma sector should go from volume to value leadership Creating new molecules has gone beyond mixing up the contents of different test tubes while holding one's breath for the result. AlphaFold from Google's DeepMind has forecast the likely shape of over 200 million distinct proteins using artificial intelligence (AI). Protein molecules interact with one another based on their shape. Alphafold's database, available free, has eased a path ahead for drug developers. The first drug to be synthesized using AI, done by Insilico Medicine for a form of pulmonary disease, is past its early-phase trials. Indian PhDs are relatively inexpensive to recruit than their global counterparts. Why shouldn't Indian pharma players marshal hundreds of them to identify potential targets from the protein database and develop them as drugs for particular diseases? Biologics and biosimilars are exciting new areas of innovation. Identifying new applications for existing drugs is now a challenge of Big Data, involving an analysis of how people respond to medicines in various ways beyond the intended effects. Semaglutide was originally developed for diabetes, but has stormed sales charts as a weight-loss drug. Also Read: Anonymized medical data should be given an additional privacy shield The scope for innovation in pharma is vast. Efforts are on to switch from batch-wise drug-making to continuous production, marking gains of cost and quality. Process innovation had been Indian pharma's forte before 2003, when product patents kicked in. Aided by tech enablers, the industry can apply similar skills of process redesign to today's needs, surely. The use of tokens on a blockchain could tackle the menace of fake drugs, a problem that haunts much of the world. Also crying out for innovation is the efficiency of drug delivery, whether through skin patches, better inhalers or capsules modified to release dosages at variable speeds. Meanwhile, millions of wearable devices are picking up vital data in large volumes that insurers and researchers would love to get their hands on. Clarity on how this data can be effectively used without any privacy violation could open up new prospects too. All said, even though a US tariff cloud seems to hang over generic exports, there's no dearth of opportunity for Indian pharma.
Mint
11-07-2025
- Business
- Mint
Top three stocks to buy today—recommended by Ankush Bajaj for 11 July
On Thursday, 9 July 2025, the Indian stock market struggled to find direction and eventually leaned to the downside, weighed by weakness across several sectors and limited broad-based participation. Despite some gains in select index heavyweights, the broader market sentiment reflected a cautious pullback after recent upswings. Top 3 Stocks Recommended by Ankush Bajaj Buy: Glenmark Pharma — Current Price: ₹1904.00 Why It's recommended: Glenmark has made a fresh lifetime high, signaling strong bullish sentiment and strength in price action. On the lower timeframes, the stock is consistently trading above key moving averages, reinforcing the prevailing uptrend. It has shown resilience amid recent market volatility and is establishing a long-term bullish trend that may extend further. The structure remains technically sound, supported by strong price action and moving average alignment, indicating potential for continued upside toward higher levels. Key metrics: Breakout zone: Fresh lifetime high breakout Support (stop loss): ₹1855 Pattern: Lifetime high breakout with moving average alignment RSI: Not overbought; showing steady strength on both intraday and daily charts Technical analysis: The stock has entered uncharted territory by registering a new all- time high, confirming a strong continuation breakout. The price action is decisive and backed by healthy volumes, with a steady climb above previous consolidation levels. On the lower timeframe charts, Glenmark is holding well above both short-term and medium-term moving averages, signaling sustained bullish demand. The trend shows little sign of exhaustion at this stage, with the next upside zone seen around ₹1975– ₹1980 as the breakout matures. Risk factors: A close below ₹1855 would invalidate the bullish breakout setup and suggest weakening short-term momentum. Traders should stay alert for any broad market corrections or if the stock fails to hold above ₹1880 in the near term. Buy at: ₹1904.00 Target price: ₹1975– ₹1980 Stop loss: ₹1855.00 Buy: HDFC AMC — Current Price: ₹5207.00 Why it's recommended: HDFC AMC is exhibiting strong momentum as reflected by the daily RSI reading above 63, which indicates sustained buying interest without being overbought. The stock has also formed a symmetrical triangle pattern on the daily chart, a classic continuation pattern suggesting that the recent consolidation is likely to resolve higher. The structure is bullish and favors a potential breakout toward the ₹5270– ₹5280 zone in the near term. Key metrics: Breakout zone: Triangle pattern breakout on the daily chart Support (stop loss): ₹5170 Pattern: Symmetrical triangle continuation RSI: Above 63 — strong bullish momentum Technical analysis: HDFC AMC has been consolidating within a well-defined triangle pattern and is now showing signs of an upward breakout. The price action is supported by rising RSI and strong positioning above short-term moving averages, indicating sustained institutional interest. With volumes starting to pick up and momentum indicators favoring buyers, the stock looks poised to move toward ₹5270– ₹5280 in the short term. Risk factors: A close below ₹5170 would negate the bullish breakout setup and may invite short-term weakness. Traders should watch for price stability above ₹5200 to maintain bullish bias. Buy at: ₹5207.00 Target price: ₹5270– ₹5280 Stop loss: ₹5170.00 Buy: Bajaj Finance — Current Price: ₹947.65 Why it's recommended: Bajaj Finance is showing a steady recovery with the daily RSI hovering near 60, indicating improving momentum. The stock has formed a triangle pattern on the daily chart, suggesting a base formation after recent correction. Additionally, on the 15-minute timeframe, Bajaj Finance has already given a triangle breakout, further supporting the potential for a short-term surge. These multiple timeframe signals make the setup attractive for a move toward ₹970. Key metrics: Breakout zone: Triangle breakout on 15-minute chart, daily triangle base Support (stop loss): ₹935 Pattern: Triangle breakout across daily and intraday charts RSI: Near 60 — improving momentum Technical analysis:The stock has been consolidating in a narrowing range and has now broken out on the lower timeframe, confirming near-term strength. The daily chart also reflects a triangle base pattern, which often precedes directional moves. RSI is supportive, and the price has reclaimed short-term moving averages, indicating improved sentiment. The setup targets ₹970 in the short term, with potential for more if volume expansion continues. Risk factors: A close below ₹935 would invalidate the short-term breakout and suggest weakness in the current structure. Failure to hold above ₹945 intraday may also reduce upside conviction. Buy at: ₹947.65 Target price: ₹970.00 Stop loss: ₹935.00 Market Wrap – July 11, 2025 (Friday) The Nifty 50 gave up early gains and settled at 25,355.25, up by 120.85 points or 0.47%, but the move lacked conviction as several key sectors failed to support the momentum. The BSE Sensex ended at 83,190.28, adding 345.80 points or 0.41%, but mostly on the back of select stocks. Bank Nifty managed a modest gain of 257.55 points or 0.45% to close at 56,956.00, yet activity remained range-bound within financials. On the sectoral front, signs of fatigue were evident. PSU Bank slipped 0.80%, the India. Consumption Index fell 0.67%, and Infrastructure declined 0.63% — all indicating profit- taking in previously active themes. Meanwhile, defensive names tried to offer support, with Realty gaining 0.72% and Metals inching up 0.42%, but failed to lift overall sentiment. Among individual performers, IndusInd Bank and Maruti Suzuki rose 1.44% each, while Tata Steel climbed 1.04%, reflecting selective institutional interest. However, broader weakness was seen as stocks like Bharti Airtel dropped 2.73%, Asian Paint declined 1.91%, and HDFC Life Insurance also slipped 1.91%, showing selling pressure in defensives and recent gainers alike. Nifty Technical Analysis The Nifty ended Thursday's session on a notably weak note, falling by 120.85 points or 0.47% to close at 25,355.25. This marked a clear break from the recent tight-range activity seen over the past 7–8 sessions. The index not only closed at the lowest point of the day but also decisively moved below key intraday supports, indicating that bears are regaining control. On the daily chart, the range breakdown reflects a loss of short- term momentum, while on the hourly timeframe, Nifty appears to be breaking down from a bearish pennant pattern, with the next visible support zone around the psychological 25,000 mark. From a broader technical perspective, the index still trades above its key daily moving averages, with the 20-day simple moving average placed at 25,243 and the 40-day exponential moving average at 25,011. This keeps the medium-term trend structure intact. However, on the hourly chart, Nifty is now trading below both the 20-hour SMA (25,457) and the 40-hour EMA (25,443), which highlights increasing short-term weakness and a shift in directional bias toward the downside. Momentum indicators are showing a clear deterioration across timeframes. On the daily chart, the Relative Strength Index (RSI) has dropped to 55, reflecting weakening bullish momentum, while the MACD has slipped further to 199, with a negative crossover now confirmed below the signal line. The hourly RSI has declined sharply to 33.8, entering oversold territory, while the MACD is deeply negative at –26, also below its signal line, confirming short-term bearish control. These readings reinforce the emerging downside risk and support the breakdown seen in price structure. In the derivatives segment, options data remains distinctly bearish. The total Call Open Interest stands at 20.15 crore, significantly outweighing the Put OI of 12.53 crore, resulting in a sharp net OI difference of –7.63 crore. This signals aggressive call writing and lack of put support near current levels. Intraday change data further confirms the bias, with Call OI rising by 2.97 crore contracts and Put OI increasing only marginally by 24.03 lakh contracts, creating a net change of –2.73 crore—a sign of fresh bearish positioning. Strike-level data shows that 25,400 now holds both the highest Call OI and the highest Call addition, marking it as a firm resistance level. Meanwhile, the 25,350 strike has emerged as the Put heavy zone, with both the highest Put OI and the most additions, setting it up as a potential pivot. However, with prices closing below this level, further pressure cannot be ruled out. Volatility remains contained, with India VIX slipping by 2.24% to 11.67, showing that despite the breakdown, traders are not yet pricing in panic or sharp volatility expansion. Market breadth appeared negative, in sync with the directional move and weakening intraday signals. In summary, while the medium-term trend remains intact above the 25,000–25,050 zone, short-term technicals have clearly weakened, with price breaking out of a multi-day range on the downside and momentum indicators confirming the move. Unless the index quickly reclaims the 25,400–25,450 zone, the bias will remain negative. Traders should stay cautious and look for fresh long entries only near major support zones around 25,000, with strict stop-loss discipline. A sustained close below 25,300 may open the door for deeper cuts in the coming sessions. Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
